Abstract submission opens: May 1, 2018
Abstract submission closes: September 30, 2018
The American Society for Experimental Neurotherapeutics (ASENT) was established for leaders in academia, government, advocacy and industry who are dedicated to advancing the development of improved therapies for diseases and disorders of the nervous system. The 21st ASENT Annual Meeting, slated to take place in March of 2019 in Rockville, MD will offer participants the most current information in the field of neurotherapeutics.
ASENT abstract submission fees are very low to encourage increased participation. A $50 non-refundable fee will be charged for all abstracts submitted by non-members. A $25 non-refundable fee will be charged for all abstracts submitted by members. Your abstract will not be considered complete if payment is not submitted.
Abstracts are peer reviewed, and all accepted abstracts will be presented at the poster sessions. Authors of accepted abstracts will also be considered for platform presentations in the Pipeline Session.
All accepted abstracts will be published online in Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics, unless the submitting author requests otherwise.
All submitters will receive notification of the status of their abstracts and presentations for the meeting by December 10, 2018. All presenters are expected to cover their own travel and lodging, and pay the annual meeting registration fees.
ASENT's Abstract Review Committee will review and make the final decision of abstract approval based on scientific merit and program considerations. ASENT requires that an author attends the Annual Meeting to present the work. If the first author is not planning to attend the Annual Meeting, then a co-author may present the work. Changes in presenter should be emailed to firstname.lastname@example.org and include the abstract title, ID number, and the presenter’s name.
- Abstracts that have been presented at other recent scientific meetings can be submitted for consideration.
- Abstracts must be submitted in English and all presentations will be in English.
- Abstracts must conform to the instructions provided for electronic submission.
- Abstract Style: The abstract should describe original research broadly relevant to the goal of ASENT, which is to encourage and advance the development of improved therapies for diseases and disorders of the nervous system. Please check your abstract carefully for typographical errors, misspellings, etc.
- Title: The title should use capital letters where appropriate (not all capital letters). Do not use abbreviations in the title unless they are universally understood in the field (e.g. EEG, MRI, PET Scan).
- Author Names and Affiliations: List authors followed by affiliations, separated by semi-colons. Superscript numbers should be used after each author's name in cases where there are multiple affiliations.
- Abstract Structure: The body of the abstract should be one paragraph with no subheadings but organized as follows:
- A sentence stating the study's purpose.
- A brief description of methods.
- A summary of the results.
- A statement of conclusions reached. Do not state simply the "the results will be discussed."
- The body of the abstract should include a maximum of 350 words per abstract.
- Do not include tables or graphs.
- Abbreviations: Use standard abbreviations sparingly. Spell out abbreviations when first used.
- Literature Citations: Literature citations are ordinarily not provided in abstracts. In cases where citations are necessary, these should be included in the body of the abstract and formatted to include First Author, et al, Journal name, Volume: Pages, and Year.
- Drug Names: Use of both product and chemical names (capitalized) is acceptable.